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was administered intramuscularly 20 minutes after MKH-Me admin-
istration. When compared with group of animals treated only with 
morphine, statistically significant increase in analgesic effect was 
detected 10, 30, 40, and 50 minutes after morphine administration 
(P < 0.05). Pretreatment with MKH-Na did not affect morphine 
analgesic effect.
Conclusion: According to results of this study, it can be presumed 
that after intramuscular morphine administration methyl ester of 
monoketocholic acid increases morphine transport into the central 
nervous system and consequently analgesic effect as well. Further 
research on bile acids-morphine interaction both in vitro and in vivo 
is necessary to completely elucidate the mechanism of this interaction 
and increase in morphine analgesic effect.
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Introduction: Bile acids (BAs) are essential for the absorption, trans-
port, and distribution of dietary lipids, vitamins, and xenobiotics. 
As transcription factor ligands (eg, of FXR), they influence signaling 
pathways regulating lipid, glucose, and energy homeostasis.1 First 
studies indicate that BAs are also able to influence the expression 
of microRNAs (miRNAs), a class of small noncoding RNAs that is 
able to inhibit protein translation.1,2 Several different hepatic disease 
states as well as the intake of certain hepatotoxic drugs can induce 
cholestasis, a condition associated with elevated bile acid levels in 
hepatocytes.
We aimed to comprehensively investigate the impact of BAs on 
the human mRNAome and miRNAome, focusing on the question, 
to which extent elevated BAs may have the potential to influence the 
expression of genes involved in drug metabolism and disposition and 
signaling pathways driven by miRNAs.
Patients (or Materials) and Methods: Two batches of primary 
human hepatocytes were treated with 50-µM chenodeoxycholic 
acid (CDCA) or vehicle (DMSO) for 48 hours. Global mRNA and 
miRNA profiling was performed using next-generation sequencing. 
Adapter-ligated RNA samples were reverse-transcribed and enriched 
by PCR. After cluster generation (TruSeq PE Cluster Kit v3-cBot-
HS (Illumina)) sequencing was performed on the Illumina HiSeq 
2000 (TruSeq SBS Kit v3-HS (Illumina)). RNA-reads were quality-
checked (fastqc) and aligned to the genome (tophat v1.3.3). The 
GLM procedure (edgeR, R package) was used for statistical analysis 
comparing the mRNA and miRNA expression values across the 
different conditions.
Results: A total of 702 genes were significantly decreased, 1345 
genes and 71 miRNAs were significantly increased in expression in 
BA-treated cells. Besides classical FXR targets involved in BA trans-
port and metabolism (eg, CYP7A1, BSEP) that served as positive 
controls for repression and induction by BAs, respectively, many 
genes coding for proteins involved in drug metabolism appear to be 
affected and in many cases down regulated by BAs. Examples include 
genes encoding members of the CYP1A, CYP2C and CYP3A and the 
SLC transporter family as well as members of the GST, SULT, and 
UGT family. Notably members of the miRNA families 320 and 548 
appeared to be strongly regulated by CDCA.
Conclusion: BAs have the potential to significantly modulate the 
expression of genes involved in the biotransformation of drugs and, 
thus, may have a significant impact on drug metabolism and dispo-
sition. The detection of differentially expressed miRNA molecules 
extends the spectrum of regulatory pathways influenced by BAs.
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Introduction: Liver dysfunction is frequent in CHF and characterized 
by a predominantly cholestatic enzyme profile that is associated with 
disease severity and prognosis. Thus, we propose a cardio-hepatic 
syndrome in CHF. Future studies are needed to clarify the exact 
mechanisms of organ interaction. The aim of the study was to evalu-
ate the efficacy of various therapy of CHF to cessation the symptoms 
of “cardio-hepatic” syndromes.
Patients (or Materials) and Methods: A total of 125 patients with 
IHD and CHF NYHA class II–III were enrolled in this open, con-
trolled trial. The protocol was approved by local ethical committee. 
All patients after randomization were included into group; control and 
main. In the control group, patients were treated by standard combina-
tion and in main group additionally received badci (NAD-containing 
drug) in dose of 180 mg once daily for 14 days. Symptoms of CHF, 
ECG, EchoCG, and markers of hepatic function were clinically com-
pared. Blood chemistry analysis included the measurements of circulat-
ing level of total and direct billirubin, ALT, AST, γ -glutamyltransferase 
(GGT), and alkaline phosphatase (ALP), NAD, NAD/NADH levels 
and the content of proinflammatory cytokines (IL-1 and IL 6) were 
studied. Data were analyzed with SPSS 10.0 statistical package.
Results: In patients with stable CHF without marked systolic dys-
function, changes of liver abnormalities were common by typically 
by small amplitude, particularly in those patients with an ejection 
fraction < 35%. Middle elevation of alkaline phosphatase and total 
billirubine as well as mild decrease of albumine were observed. The 
redox potential of NAD/NADH in the plasma was reduced by 21% 
without significantly changes in the total content of pyridine nucleo-
tide. We postulated that hypoxia might play a pathophysiologic role 
linking CHF to liver injury. The content of IL6 increase up to 112% 
in patients with average NYHA class 2.3 (0.2) (according to J. Cohn 
HF score, 1986) in the mechanism of which leads the ability of IL-6 
binds to hepatocytes by interacting with an 80-kd membrane gly-
coprotein (gp80). Including in the therapy NAD-containing drug, 
nadcin (180 mg once daily IV) significantly improved hepatic func-
tion and cholestatic abnormalities, and as very important decrease 
up to normal level the content of IL6 and IL-1β in patients with CHF 
without pronounced left ventricle dysfunction.
Conclusion: Cessation of abnormalities of the hematologic system 
and decrease in the content of IL-6, as 1 of the key regulators of 
the initial steps of liver regeneration and IL-6–dependent signal-
ing response mechanism under treatment with exogenous NAD-
containing drug (in form of nadcin) restores the cell redox-potential, 
occurs beneficial effect on the cytokine system and as a result occurs 
deremodeling of liver functioning system, opens the new era in the 
CHF therapy and avoid the cardio-hepatic syndrome formation.
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Introduction: Acute rejection (AR) and delayed graft function 
(DGF) are 2 main adverse early posttransplant events that one 
would like to avoid. DGF conventionally defined as requirement 
for dialysis during the first postperative week is a form of acute 
renal failure that results in posttransplant oligouria, increases risk of 
AR, and decreases graft survival. Higher incidence of DGF in renal 
transplant recipients treated by CsA was described previously, but 
the mechanism of this effect has not been explained yet. The aim 
of this study was to compare blood concentrations of CsA and its 
metabolites AM1, AM9, and AM4N in patients with immediate and 
DGF renal function.
Patients (or Materials) and Methods: Fourteen adult renal transplant 
recipients (8 males) were prospectively observed during the first 3 
months. The therapy was based on CsA microemulsion (Sandimun 
Neoral® or Equoral®) in combination with mycophenolate and 
prednisone and was adapted in accordance with guidelines and clini-
cal outcomes. First dose of CsA (4–8 mg/kg) was administered in 
the day of transplantation. On the basis of clinical status confirmed 
by serum creatinine level and creatinine clearance the subjects were 
divided in to 2 groups with immediate graft function (IF-7 patients) 
and with DGF (7 patients). The CsA and the metabolites C0, C2, and 
C4 concentrations were analyzed using LC-MS/MS method in days 
1 to 7, 14, 21, and 28.1
Results: Significant higher creatinine levels and significant lower 
creatinine clearance were found in DGF group (P < 0.05). During 
the first month the CsA C0 were significantly higher (237 [127] 
μ g/L vs 170 [72] μ g/L; P = 0.0002) while C2 and AUC0-4 were 
lower (698 [320] μ g/L vs 919 [412] μ g/L, 2162 [830] μ g*h/L vs 
2610 [1002] μ g*h/L; P < 0.01). The highest concentrations dif-
ferences were found in AM4N metabolite: C0 (66.5 [61] μ g/L vs 
7.5 [7.4] μ g/L), C2 (111 [93] ug/L vs 41 [34] ug/L), C4 (134 [131] 
μ g/L vs 32 [22] ug/L), AUC0–4 (415 [352] μ g*h/L vs 121 [91] 
μ g*h/L). AM4N/CsA ratio: C0 (0.3 [0.28] vs 0.05 [0.04]), C2 (0.19 
[0.17] vs 0.05 [0.04]), C4 (0.25 [0.25] vs 0.06 [0.04]). All results 
were significant for P < 0.0001. Similarly C0, C2, C4, AUC0–4 of 
AM1 and AM1/CsA ratio were significantly lower in DGF group 
(P < 0.001). The graft function in DGF group recovered between 
1 week and 2 months and the differences of CsA and metabolites 
concentrations disappeared.
Conclusion: Metabolismus of CsA in patients with IF and DGF was 
different. Higher concentrations of AM4N and AM1 should be cause 
or markers.Therefore, TDM of CsA in combination with fenotypiza-
tion is recommended.
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Introduction: Streptomycin, as other aminoglycosides, exhibits 
concentration-dependent bacterial killing but has a narrow thera-
peutic window. It is primarily eliminated unchanged by the kidneys. 
Data and dosing information to achieve a safe regimen in patients 
with chronic renal failure undergoing hemodialysis (HD) are scarce. 
Although main adverse reactions are related to prolonged, elevated 
serum concentrations, literature recommendation is to administer 
streptomycin after each HD.
Patients (or Materials) and Methods: We report the case of a patient 
with end-stage renal failure, undergoing HD, who was successfully 
treated with streptomycin for gentamicin-resistant Enterococcus 
faecalis bacteremia with prosthetic arteriovenous fistula infection. 
Streptomycin was administered intravenously 7.5 mg/kg, 3 hours 
before each dialysis (3 times a week) during 6 weeks in combination 
with amoxicillin. Streptomycin plasma levels were monitored with 
repeated blood sampling before, after, and between HD sessions. A 
2-compartment model was used to reconstruct the concentration time 
profile over days on and off HD.
Results: Streptomycin trough plasma-concentration was 2.8 mg/L. 
It peaked to 21.4 mg/L 30 minutes after intravenous administration, 
decreased to 18.2 mg/L immediately before HD, and dropped to 4.5 
mg/L at the end of a 4-hour HD session. Plasma level increased again 
to 5.7 mg/L 2 hours after the end of HD and was 2.8 mg/L 48 hours 
later, before the next administration and HD. The pharmacokinetics 
of streptomycin was best described with a 2-compartment model. 
The computer simulation fitted fairly well to the observed concentra-
tions during or between HD sessions. Redistribution between the 2 
compartments after the end of HD reproduced the rebound of plasma 
concentrations after HD. No significant toxicity was observed during 
treatment. The outcome of the infection was favorable, and no sign 
of relapse was observed after a follow-up of 3 months.
Conclusion: Streptomycin administration of 7.5 mg/kg 3 hours 
before HD sessions in a patient with end-stage renal failure resulted 
in an effective and safe dosing regimen. Monitoring plasma levels 
along with pharmacokinetic simulation document the suitability of 
this dosing scheme, which should replace current dosage recommen-
dations for streptomycin in HD.
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Introduction: Mammalian hibernation is characterized by profound 
reductions in metabolism and body temperature. As a result, hibernat-
ing animals enter a state of suspended animation called “torpor,” where 
